Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Triple Negative Breast Neoplasms

Mesothelioma

Carcinoma, Non-Small-Cell Lung

Biochemically Recurrent Prostate Carcinoma

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

Carcinoma, Transitional Cell

EGFR-Mutated Non-Small-Cell Lung Carcinoma

Lung Neoplasms

Urothelial Cancer

Small Cell Lung Carcinoma

Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lymphoma, Ovarian Neoplasms, Recurrence

Triple Negative Breast Neoplasms

Prostatic Neoplasms

Brain Neoplasms, Small Cell Lung Carcinoma

Pancreatic Neoplasms, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of the Pancreas

Bladder Adenocarcinoma

Lung Neoplasms

Squamous Cell Carcinoma of Head and Neck

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

Breast Neoplasms

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

DUTHY

AMTEC IIT: Phase 2 Multiarm Study in TNBC

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

ESR1814205

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

DUART

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

ICC

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

A Study of Olaparib and Durvalumab in Prostate Cancer

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors